MX9606550A - Composiciones de polipeptidos de liberacion controlada y metodos para tratar enfermedad inflamatoria del intestino. - Google Patents
Composiciones de polipeptidos de liberacion controlada y metodos para tratar enfermedad inflamatoria del intestino.Info
- Publication number
- MX9606550A MX9606550A MX9606550A MX9606550A MX9606550A MX 9606550 A MX9606550 A MX 9606550A MX 9606550 A MX9606550 A MX 9606550A MX 9606550 A MX9606550 A MX 9606550A MX 9606550 A MX9606550 A MX 9606550A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- controlled release
- inflammatory bowel
- bowel disease
- treating inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invasion se refiere a una formulacion farmacéutica de liberacion controlada que tiene una cantidad efectiva de un polipéptido seleccionado del grupo que consiste en: (a) un receptor de factor de necrosis de tumor (TNFR), (b) receptor de interleucina-1 (IL-1R), (c) receptor antagonista de interleucina-1 (IL.1ra); (d) receptor de interleucina 6 y (e) un anticuerpo monoclonal que es inmunorreactivo contra el factor de necrosis de tumor, la interleucina 6 o interleucina 1; estando el polipéptido encapsulado en alginato. La invencion también se refiere a los métodos para tratar enfermedad inflamatoria del intestino administrando la composicion anterior a un paciente que lo necesite.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26558794A | 1994-06-24 | 1994-06-24 | |
| US265587 | 1994-06-24 | ||
| PCT/US1995/007953 WO1996000081A1 (en) | 1994-06-24 | 1995-06-22 | Controlled release polypeptide compositions and methods of treating inflammatory bowel disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX9606550A true MX9606550A (es) | 1997-07-31 |
| MXPA96006550A MXPA96006550A (es) | 1997-12-01 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| AU698393B2 (en) | 1998-10-29 |
| EP0766564A1 (en) | 1997-04-09 |
| EP0766564A4 (en) | 1998-09-23 |
| CA2192821A1 (en) | 1996-01-04 |
| US6036978A (en) | 2000-03-14 |
| WO1996000081A1 (en) | 1996-01-04 |
| NZ288997A (en) | 1999-01-28 |
| JPH10503179A (ja) | 1998-03-24 |
| AU2870995A (en) | 1996-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schwertschlag et al. | Hematopoietic, immunomodulatory and epithelial effects of interleukin-11 | |
| Seckinger et al. | Purification and biologic characterization of a specific tumor necrosis factor α inhibitor | |
| Haque et al. | Interferon gamma (IFN‐γ) may reverse oral submucous fibrosis | |
| Germann et al. | Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells | |
| Billiau | Gamma-interferon: the match that lights the fire? | |
| CN1322897C (zh) | Il－18抑制剂的应用 | |
| Bessis et al. | The type II decoy receptor of IL‐1 inhibits murine collagen‐induced arthritis | |
| DE68925226T2 (de) | Monoklonale Antikörper | |
| DE69724451D1 (de) | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen | |
| BG108514A (en) | METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES | |
| Fujioka et al. | Preparation of specific antibodies against murine IL-1ra and the establishment of IL-1ra as an endogenous regulator of bacteria-induced fulminant hepatitis in mice | |
| DK0811384T3 (da) | Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof | |
| JPH08505365A (ja) | 自己免疫疾患および炎症性疾患の治療 | |
| JPH09510444A (ja) | 自己免疫疾患の治療におけるｉｌ−１２およびｉｌ−１２アンタゴニストの使用 | |
| US7741276B2 (en) | Use of interleukin-18 inhibitors to inhibit tumor metastasis | |
| Hansen et al. | High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro | |
| Hansen et al. | Influence of interleukin‐6 (IL‐6) autoantibodies on IL‐6 binding to cellular receptors | |
| Campbell et al. | Interleukin (IL)-2, IL-4, and tumor necrosis factor-α responses during Entamoeba histolytica liver abscess development in gerbils | |
| Keegan et al. | Superinduction of the murine B cell Fc epsilon RII by T helper cell clones. Role of IL-4. | |
| Van Deuren | Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections | |
| US20020025316A1 (en) | Pharmaceutical composition containing inhibitors of interferon-gamma | |
| MX9606550A (es) | Composiciones de polipeptidos de liberacion controlada y metodos para tratar enfermedad inflamatoria del intestino. | |
| Dallman et al. | Cytokines and their receptors in transplantation | |
| Nishimoto et al. | Myeloma biology and therapy: present status and future developments | |
| CA2229590C (en) | Pharmaceutical composition containing inhibitors of interferon- gamma |